SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-046720
Filing Date
2020-02-24
Accepted
2020-02-24 17:22:40
Documents
14
Period of Report
2020-02-24
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d890302d8k.htm   iXBRL 8-K 26409
2 EX-99.1 d890302dex991.htm EX-99.1 69864
6 GRAPHIC g890302g0224235927802.jpg GRAPHIC 4588
  Complete submission text file 0001193125-20-046720.txt   238018

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA clvs-20200224.xsd EX-101.SCH 3087
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE clvs-20200224_lab.xml EX-101.LAB 18138
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE clvs-20200224_pre.xml EX-101.PRE 11419
9 EXTRACTED XBRL INSTANCE DOCUMENT d890302d8k_htm.xml XML 3356
Mailing Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301
Business Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301 (303) 625-5000
Clovis Oncology, Inc. (Filer) CIK: 0001466301 (see all company filings)

IRS No.: 900475355 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35347 | Film No.: 20645620
SIC: 2834 Pharmaceutical Preparations